Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BROLUCIZUMAB for Choroidal neovascularisation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 102 adverse event reports in the FDA FAERS database where BROLUCIZUMAB was used for Choroidal neovascularisation.

Most Reported Side Effects for BROLUCIZUMAB

Side Effect Reports % Deaths Hosp.
Visual impairment 116 17.0% 0 7
Vision blurred 106 15.5% 0 13
Eye pain 81 11.9% 0 4
Vitreous floaters 74 10.9% 0 2
Vitritis 65 9.5% 0 4
Ocular hyperaemia 62 9.1% 0 4
Off label use 62 9.1% 3 1
Subretinal fluid 62 9.1% 0 0
Retinal vasculitis 52 7.6% 0 5
Eye inflammation 50 7.3% 0 6
Visual acuity reduced 50 7.3% 0 6
Uveitis 48 7.0% 0 5
Blindness 44 6.5% 0 4
Product use in unapproved indication 38 5.6% 0 0
Drug ineffective 36 5.3% 1 1

Other Indications for BROLUCIZUMAB

Neovascular age-related macular degeneration (225) Product used for unknown indication (85) Age-related macular degeneration (73) Polypoidal choroidal vasculopathy (70) Diabetic retinal oedema (57) Macular degeneration (34) Retinal vein occlusion (29) Diabetic retinopathy (6)

Other Drugs Used for Choroidal neovascularisation

AFLIBERCEPT (2,953) RANIBIZUMAB (1,364) FARICIMAB\FARICIMAB-SVOA (306) BEVACIZUMAB (302) BROLUCIZUMAB-DBLL (104) FARICIMAB-SVOA (65) VERTEPORFIN (42) AVASTIN (12) LUCENTIS (11) TRIAMCINOLONE ACETONIDE (10)

Related Pages

BROLUCIZUMAB Full Profile All Choroidal neovascularisation Drugs BROLUCIZUMAB Demographics BROLUCIZUMAB Timeline